RSV Seasonal Vaccine Introduction and Growth Strategy

Continuing operations basis for guidance 2022 2023 Q1 Q2 Q3 Q4 FY Q1 Q2 Including COVID-19 solutions Sales (Em) 7,190 6,929 7,829 7,376 29,324 6,951 7,178 Operating profit (£m) 1,943 2,008 2,605 1,595 8,151 2,092 2,170 Earnings per share (pence) post- 32.3 34.7 46.9 25.8 139.7 37.0 38.8 share consolidation COVID-19 solutions impact Sales 1,307 466 417 183 2,373 132 41 Operating profit 194 58 141 69 69 462 118 57 Earnings per share (pence) post- 4.1 1.2 2.9 1.5 9.7 2.5 1.2 share consolidation GSK 34 14

View entire presentation